Loading clinical trials...
Loading clinical trials...
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Conditions
Interventions
Aflibercept
foselutoclax
Locations
19
United States
California Retina Consultants
Bakersfield, California, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Salehi Retina Institute Inc.
Huntington Beach, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Advanced Vision Research Institute
Longmont, Colorado, United States
Rand Eye Institute
Deerfield Beach, Florida, United States
Start Date
August 23, 2023
Primary Completion Date
January 21, 2025
Completion Date
April 8, 2025
Last Updated
August 5, 2025
NCT07425522
NCT07308639
NCT07449936
NCT07449923
NCT06439576
NCT07228559
Lead Sponsor
Unity Biotechnology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions